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Abstract
Capsaicin is the active compound responsible for the pungency of hot chilli . Research has discovered its ability to desensitize periph-
eral nociceptive fibers which is useful in treating chronic pain disorders, specifically neuropathic pain syndromes. Capsaicin treatment 
comes in a variety of mediums including patches and creams and has been clinically proven to bring relief to patients with disorders 
such as post herpetic neuralgia, chronic regional pain syndrome and HIV related neuralgia . Exciting new forms of treatment are also 
in development and promise breakthroughs in the near future in this relatively young field of capsaicin-based analgesia.
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Introduction
Chronic pain syndromes are debilitating, robbing many of their 
quality of life and productivity while putting them at additional 
risk of mental health disorders. Many do not find relief despite 
extensive treatments. This has prompted research into finding 
a compound that will present a viable alternative to traditional 
analgesics, especially opiates which carry an additional risk of 
addiction. Capsaicin, the compound responsible for the pungen-
cy of the capsicum family and an example of a vanilloid, has 
been used as an analgesic agent for thousands of years. Recent 
research has proven just how well suited it is as a treatment for 
a subset of chronic pain disorders especially neuropathic pain. 
This paper will look at the mechanisms of nociception that 
are targeted by this treatment, the properties of capsaicin and 
its receptor, TRPV1, that make it so effective. Its clinical applica-
tions and limitations will also be examined to give a glimpse of 
what research has discovered and where it is taking us.
Mechanisms of Subcutaneous Primary Nociception
Nociception is the sensation of noxious stimuli perceived by no-
ciceptive receptors which are usually found in the skin (Caterina 
& Julius, 2001), although they can also be found viscerally. It is 
the first step toward the sensation of pain which is the result 
of a complicated multilayered process including central gating 
controls and peripheral activity (Hunt, 2009). Nociception itself 
is a complex process with aspects that take place in both the 
central (CNS) and peripheral nervous systems (PNS). 
There are two general categories of subcutaneous nociceptive 
primary afferent neurons, myelinated A-fibers and unmyelinated 
C-fibers. Not all A-fibers are sensitive to nociceptive stimuli, Aβ 
fibers are large rapidly conducting fibers responsible for touch 
and proprioception, and only Aδ fibers which are smaller and 
slower conductors are involved in nociception (Khalid & Tubbs, 
2017). Lightly-myelinated Aδ fibers are associated with acute 
pain or first pain which is characterized by lancinating, stabbing, 
or pricking pain that is felt immediately after exposure a nox-
ious stimulus. Unmyelinated C-fibers are very slow conductors 
and are responsible for second pain which is characterized by 
the more global sensations of throbbing, burning or cramping 
pain (Hunt, 2009; Dubin & Patapoutian, 2010).
Noxious stimuli are usually categorized as either heat (H), cold 
(C), or mechanical (M). Primary nociceptive afferent fibers are fur-
ther classified according to the type of stimuli that they respond to, 
for example C-MH, A- MH. The most common C fibers are poly-
modal, meaning they respond to multiple types of stimulation such 
as C-MC, C-MH and C-MHC. There is also a subgroup of C-fibers 
known as silent C-MiHi that only become sensitive to noxious me-
chanical or thermal stimuli after he area has become sensitized by 
inflammation. Most A-fibers are heat- or mechano- sensitive (A-H, 
A-M, A-HM) (Dubin & Patapoutian, 2010).
Nociceptors have a variety of voltage gated channels that en-
code the intensity of the stimulus (Dubin & Patapoutian, 2010). 
They also release neuropeptides that transmit input further up 
the neural axis. For example, when C-fibers are triggered they 
release glutamate and substance P (Hanpaa & Treede, 2012). 
When the skin is injured it undergoes physiological changes 
that protect it from further damage and promote healing, known 
as inflammation. There are two subgroups of C-fibers. One of 
them expresses the trkA receptor which binds to nerve growth 
factor (NGF) and synthesizes neuropeptides such as CGRP 
and substance P. When they are triggered they contribute to 
inflammation and healing at the site of the injury (Hunt, 2009). 
Symptoms of the inflammatory state include flare or reddening of 
the immediate area and increased sensitivity to both innocuous 
and noxious stimul,i both in the immediate and surrounding area. 
The increased sensitivity is due to a reduced threshold of exci-
tation in the C-fibers (Dubin & Patapoutian, 2010) and increased 
receptor expression and excitation (Lebovitz, et al., 2012).
There is a second subgroup of C-fibers that do not have a role 
in inflammation, instead they display the Ret receptor that binds 
to GDNF and express PAP that breaks down ATP to produce 
adenosine that, in turn, binds to the A1 receptor and reduces 
nociception. In fact, intrathecal application of GDNF has been 
shown to reduce neuropathic pain symptoms (Hunt, 2009).
C-fibers that are constantly in a state of excitation, such as 
those in a chronic pain state, will release a constant flow of glu-
tamate known as a glutamate barrage. This barrage may result 
in physiological changes to the dorsal root ganglion and higher 
pain areas of the brain that increases their sensitivity and excit-
ability which is known as central sensitization. Descending con-
trols may also have an impact on determining the sensitization 
of dorsal root neurons (Hunt, 2009). Central sensitization may 
also impact the sensitivity of A-fiber neurons, which don’t usual-
ly become sensitized, causing even innocuous stimuli to register 
as painful (Baron, 2006). This may be a result of synapses that 
they form with neurons that have been sensitized by C-fiber 
barrage (Hunt, 2009).
Peripheral sensitization may also occur post-injury as a result of 
physiological changes which may contribute to the development 
of neuropathic pain syndromes (Gilron, Baron, & Jensen, 2015)
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The role that C-fibers and Aδ- fibers play in the process of 
nociception is definitely an important one which makes them a 
worthwhile target in the field of analgesia. These afferent neu-
rons share a receptor TRPV1 which is expressed on all C-fibers 
and a subset of Aδ fibers (Hunt, 2009; (Lebovitz, et al., 2012), 
this means that if it can be shut off of blocked then peripheral 
nociceptive input can be greatly minimized or even neutralized.
Targeting TRPV1 is especially prized because it allows a two-
pronged strategy against pain. Not only does targeting it , target 
the beginning of the pain pathway (Trevisani & Szallasi, 2011; 
Wagner, Roth-Daniek, Sell, England, & Kern, 2012), but it also 
blocks the glutamate barrage which allows the body to break 
the pain cycle common in chronic pain patients.
TRPV1
In 1990, the study of a more potent capsaicin analog, resinifer-
atoxin (RTX), led to the discovery of a new receptor known as 
TRPV1. It’s name comes from the amino acid sequence that des-
ignates it’s membership in a family of receptors first identified in 
fruit flies. In 1969 a mutation was identified on a visual receptor 
of a fruit fly, instead of a sustained depolarizing after exposure 
to light, these mutated receptors showed only transient depo-
larizing response to light, giving the family of receptors the name 
transient receptor potential or TRP. The second part of its name, 
V1, comes from the amino acid sequence that was identified that 
marked it as a vanilloid receptor (Caterina & Julius, 2001). The 
amino acid strain was first designated VR1 but when it was joined 
to the receptor family it was abbreviated to TRPV1.
The discovery of TRPV1 led to the discovery of a subset 
of thermal-sensitive TRP-type receptors which are also called 
thermoTRPs (Trevisani & Szallasi, 2011). Other members of 
this family include TRPV2, TRPV3 and TRPV4. TRPV1 is highly 
expressed on normal nociceptive C-fibers and Aδ-fibers and 
after inflammation show increased upregulation and sensitivity 
(Lebovitz, et al., 2012). It is part of the nociceptive pathway and 
is activated by a variety of stimuli including protons, noxious 
heat, phorbol esters, fatty acids as well as vanilloids like cap-
saicin and RTX. The receptor only experiences maximum acti-
vation when activated by multiple types of stimuli (Vyklicky, et 
al., 2008), which is consistent with the polymodal nature of the 
C-fibers that are involved in nociception.
TRPV1 has been proved to be involved in many forms of 
pathophysiology including inflammatory bowel syndrome (IBS), 
osteoarthritis, rheumatoid arthritis, post herpetic neuralgia 
(PHN) and cystitis amongst others (Andreev, et al., 2013). This 
makes understanding this receptor necessary for the treatment 
of many different disorders.
There are two ways that TRPV1 can be targeted pharmaco-
logically, either it can be desensitized by vanilloids or blocked 
by antagonists. There are two types of desensitization, acute de-
sensitization and tachyphylaxis, which is a reduction in response 
to noxious stimuli as a result of repeated application (Vyklicky, 
et al., 2008). There is also a difference between high dosage and 
low dosage desensitization such as between the short-term 
refractory period that takes place after any application of a 
vanilloid and longer lasting defunctionalization that takes place 
after the administration of a high dosage application (Finch & 
Drummond, 2015) (Trevisani & Szallasi, 2011). 
Multiple biomechanisms have been discovered by researchers 
to have a role in the process of sensitization and desensitiza-
tion of the TRPV1 receptor including the phosphorylation and 
dephosphorylation of the receptor (Trevisani & Szallasi, 2011), 
although the process isn’t fully understood. The dramatic influx 
of Ca2+ ions in the primary afferent neurons that takes place 
during vanilloid applications have also proved to be a part of 
the long-term desensitization mechanism (Vyklicky, et al., 2008). 
Vanilloid induced messenger plasticity, which refers to changes 
in the expression of neuropeptides on the receptor such as 
a decrease of the proinflammatory neuropeptide SP and the 
increase of analgesic peptide galanin, and is also part of the long-
term desensitization or ‘defunctionalization’ associated with the 
application of high dosage capsaicin.
Antagonists that block the TRPV1 receptor are a popular ave-
nue of research, but many promising leads often lead to disaster. 
These compounds often induce spontaneous hypothermia in 
humans making them impractical for use. However, there have 
been promising breakthroughs by a group in Russia with a com-
pound that only partially blocked the receptor which shows 
that partial blockage of the receptor may be a better outcome 
than a full blockage (Andreev, et al., 2013). This is backed up 
by research that has shown that partial binding is enough to 
activate the TRPV1 receptor and that there are multiple levels 
of activation based on the state of binding of the receptor (Hui, 
Liu, & Qin, 2003).
There used to be a theory that the main function of TRPV1 
is thermoregulation. This was based on its role in thermal sensi-
tivity and the hypothermic effect of capsaicin and TRPV1 antag-
onists, but this was later mostly debunked (Trevisani & Szallasi, 
2011). Other studies have also shown that the gene deletion 
of TRPV1 in mice still allowed for a level of noxious thermal 
sensitization (Dubin & Patapoutian, 2010).
TRPV1 is the therapeutic focus of a common analgesic and 
other drugs on the market. Paracetamol or acetaminophen is 
thought to interact with TRPV1 as part of its analgesic mecha-
nism. Also drugs such as Taramidol which is used to treat fibro-
myalgia and nefopam, a benzoxazocine analgesic, also interact 
with TRPV1. There are also compounds in Eastern medicine that 
may target TRPV1 (Trevisani & Szallasi, 2011).
Capsaicin
Capsaicin, or 8-methyl-N-vanillyl-noneamid, is the compound 
responsible for the pungency of hot chili peppers (Factor, et al., 
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2011) which are of the genus capsicum (Finch & Drummond, 
2015). Any ingestion of hot chili will cause a painful burning sen-
sation. However, perhaps ironically, capsaicin has been proved 
to have extensive analgesic qualities. It is also a potential neu-
rotoxin and large doses can cause permanent nerve damage 
(Trevisani & Szallasi, 2011).
For thousands of years capsaicin extracts were used as part 
of native medicine as a primitive analgesic. Aztec physicians may 
have used it to treat tooth ache and sources show that RTX, 
which is derived from the latex of the palm Euphoria Resinifera, 
may have been used in Ancient Rome to treat the arthritis of 
the Emperor Augustus. In Northern India a native plant contain-
ing capsaicin called bhut jolokial has been used by the people 
who live there to treat arthritis (Finch & Drummond, 2015). 
Modern pharmacy, however, was late to discover its qualities 
and did not recognize it’s potential until the year1878 (Trevisani 
& Szallasi, 2011).
The Hungarian chemist Endre Hӧgyes is credited with the 
discovery of the effect of capsaicin on sensory fibers but his 
find remained lost until the turbulent years and scientific inno-
vation of World War Two. Another Hungarian chemist, Nicholas 
(Miklόs) Jancsό further developed the use of capsaicin by devel-
oping its potential as a promising analgesic. In the 1970’s capsa-
icin research exploded, with the number of papers on record 
jumping exponentially. Capsaicin continues to be of a topic of 
interest for the general scientific community and continues to 
be extensively researched until today (Trevisani & Szallasi, 2011).
Originally the analgesic properties of capsaicin were though 
to come from its counterirritant and warming properties 
(Hanpaa & Treede, 2012) but now we know that there are many 
mechanisms involved (Vyklicky, et al., 2008). It is a TRPV1 agonist 
(Factor, et al., 2011) and it is the complex interaction between 
TRPV1 and capsaicin that is the crux of its analgesic abilities.
Initial exposure to capsaicin activates the TRPV1 ligand gated 
channels on the primary afferent nociceptive neurons which 
cause depolarization, the initiation of an action potential and 
transmission of a pain signal to the spinal cord (Backonja, et 
al., 2008). This is followed by a lasting refractory period know 
as desensitization (Factor, et al., 2011) and if the dose is high 
enough it generates a longer lasting local desensitization which 
is also known as defunctionalization (Finch & Drummond, 2015).
In high dose applications when TRPV1 is activated, high lev-
els of calcium enter the cell overwhelming the mitochondria 
and causing apoptosis. The nociceptive nerve fibers in the area 
where the capsaicin is administered begin to die which prevents 
the initiation of new nociceptive input, causing a defunctional-
ization of the nociceptive ability in that area.) After the applica-
tion of a high dose capsaicin patch for one week there was an 
80% decrease in the density of epidermal nerve fibers (ENFs). 
However, if the dosage is not too high the damage is reversible, 
which was corroborated by the study. Partial regeneration was 
present twelve weeks after the treatment and complete re-
generation at twenty-four weeks (Wallace & Pappagallo, 2011). 
This is consistent with the pain relief that patients who use high 
dosage capsaicin treatment experience, often pain relief lasts for 
up to three months per application (Finch & Drummond, 2015).
This is one of the reasons that capsaicin is so well suited to 
treating chronic pain, especially neuropathic pain. Long lasting, 
comprehensive relief without daily drug use is very attractive 
for chronic pain sufferers. Also, the ability of capsaicin to tempo-
rarily destroy nociceptive nerve endings provides a way to cut 
off nociceptive input, the glutamate barrage to the spinal cord. 
This allows the spinal cord and higher pain areas to minimize or 
perhaps extinguish the effects of central sensitization or ‘wind-
up,’ which is the hyperactivity of neurons in the spinal cord and 
brain, due to neuroplasticity that makes them extra sensitive to 
pain input. Central sensitization is characteristic of neuropathic 
pain and extremely hard to treat. Doctors who have been using 
the high dose capsaicin patch have reported anecdotally a re-
duction in the symptoms of windup in their patients (Wagner, 
Roth-Daniek, Sell, England, & Kern, 2012).
Medications
There are many forms of capsaicin based pharmacological treat-
ments. Initially, low dose, topical creams were the form of choice, 
but studies found them to have a disappointing effect. In a compre-
hensive study they were found, at best, to have a moderate effect 
and many subjects reported poor or no effect (Trevisani & Szallasi, 
2011). The creams come in two different strengths 0.075% under 
the name Zostrix® (Finch & Drummond, 2015) and 0.025% with 
lidocaine under the name Axain® (Trevisani & Szallasi, 2011).
The most popular form of capsaicin-based treatment is the 
Quetenza® 8% patch. The dosage of the patch is significantly 
higher than the creams which allows the treatment to enable 
long-term desensitization within the treatment area. The patch 
promises relief for up to three months (Wallace & Pappagallo, 
2011) which is consistent with capsaicin mediated nerve fiber 
death.. This means that the patch only needs to be reapplied 
every three months, which greatly increases patient compliance.
The potential for capsaicin to cause irreversible nerve dam-
age may make physicians wary of using the high potency patch. 
However, a study shows that the recommended dosage of up 
to four patches per application (Wallace & Pappagallo, 2011) 
is within estimated dietary consumption of cultures that con-
sume a diet heavy in capsaicin such as Mexico, Thailand and India 
(Hanpaa & Treede, 2012).
The patch has shown to be effective for a variety of syn-
dromes and can be cut to size so that it can be applied almost 
anywhere on the body. Capsaicin’s unique mechanism of analge-
sia means that it has no known drug interactions which allows 
it to be incorporated into a treatment plan that includes other 
analgesics too (Wallace & Pappagallo, 2011). 
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Other forms of capsaicin include an injectable form that can 
be used to treat osteoarthritis, tendonitis and some forms of 
neuropathic pain. There is also an intranasal form that has been 
clinically proven to be effective in the treatment of migraines 
(Trevisani & Szallasi, 2011).
Clinical Applications
Capsaicin treatment has been adapted for the treatment of many 
disorders. The most obvious of these are pain related including 
PHN, stump pain, headaches, trigeminal neuralgia and osteoarthri-
tis amongst others (Wagner, Roth-Daniek, Sell, England, & Kern, 
2012). Interestingly, capsaicin has also been used for the treat-
ment of urinary incontinence as well (Trevisani & Szallasi, 2011).
The treatment of PHN by capsaicin has been the focus of many 
studies into the efficacy of capsaicin- based analgesia. PHN is one 
of the most common forms of neuropathic pain after chronic 
back pain and painful diabetic neuropathy (Wallace & Pappagallo, 
2011). PHN is a chronic pain disorder that develops the varicella 
zoster (shingles) virus comes out of dormancy. The treatment op-
tions of PHN are limited and often poorly tolerated which makes 
the disorder very hard to treat (Backonja, et al., 2008). However, 
multiple studies that have investigated the outcome of using a 
capsaicin patch have seen favorable results with minimal side ef-
fects and marked relief experienced by the patient (Backonja, et 
al., 2008; Wallace & Pappagallo, 2011). Some patients with HIV 
associated neuropathy have also reported relief from capsaicin 
patch treatments (Capsaicin dermal patch: a guide to its use in 
non-diabetic peripheral neuropathic pain, 2011).
A tertiary hospital studied the results of their hospital-wide 
adoption of capsaicin patches to treat non-diabetic patients 
with a variety of neuropathic pains. These included PHN, CRPS-I, 
knee arthroplasty related pain, painful scaring, femoral cutane-
ous neuropathy, HIV related neuropathy and neuroma. They 
found a 23% reduction of pain in a population of twenty patients 
that had been treated with the patches. They also noted that six 
of the patients had not found relief with any other treatment 
that they had tried so far. They also found that patients that had 
a higher basal quality of life experienced a better response to 
the drug (Gimenez-Mila, et al., 2014).
A novel way that capsaicin is being used is to facilitate rehabil-
itation for knee arthroplasty patients. Often pain following knee 
arthroplasty surgery can impede recovery and rehabilitation, 
leading to prolonged hospital stays and a more painful, prolonged 
recovery. Capsaicin has been introduced as a novel way to dull 
the pain through temporary desensitization of the local area for 
the duration of the initial recovery. This allows the patient to pro-
ceed with exercises and activities that will improve their function 
and help them get back on their feet quicker. It was expected that 
patients may report increased post-operative pain because the 
capsaicin had been applied, but pain scores were found to be well 
within range (Hartrick, Pestan, Carlson, & Hartrick, 2011).
Trials of capsaicin being used as ‘molecular scalpels’ for the 
treatment of cancer-related neuropathic pain are showing 
promising signs (Trevisani & Szallasi, 2011). The principle be-
hind this method of treatment is that physicians can use the 
neurotoxic ability of capsaicin to target very specific cells to 
treat chronic, intractable pain that cancer patients experience. 
The treatment carries obvious risks which is probably why the 
clinical applications that are being pursued right now are very 
limited, but the potential of this technique is very exciting.
Drawbacks
Although capsaicin is an exciting new frontier in analgesia it has 
some risks and limitations that must be addressed. Exposure of 
the mucosa of the throat to capsaicin can cause coughing and 
bronchoconstriction. However, bronchoconstriction from such 
a scenario is very rare and even coughing had a very low inci-
dence rate during the clinical trials (Wallace & Pappagallo, 2011).
Capsaicin can only be applied to a local area. In high doses 
that would be needed to give systemic relief it can cause a drop 
in body temperature and may be cardiotoxic (Lebovitz, et al., 
2012). The hypothermic effect of capsaicin is posited to be a 
result of the defunctionalization of the TRPV1 receptor. This 
warps the thermosensitivity of the preoptic heat sensors and 
fools the animal into thinking that they are warm. This is re-
flected in the animal’s loss of ability to regulate their own body 
temperature (Trevisani & Szallasi, 2011). 
Researchers have also found a correlation between a diet high 
in spicy food and an elevated risk of cancer. However, further 
research needs to be done to see if this is applicable to all forms 
of capsaicin exposure or just ingestion of capsaicin. Capsaicin 
is poorly metabolized by the skin (Wallace & Pappagallo, 2011) 
so topical application may not carry the same risk of ingestion.
The patch system, despite having many advantages, has the 
drawback of needing a minimal infrastructure and attending 
medical personnel to a be able to incorporate them into a treat-
ment plan (Gimenez-Mila, et al., 2014). Also, they often require 
the administration of a local topical anesthetic such as Lidocaine 
before application due to the sensation of painful burning that 
is experienced during the hour long application time (Wagner, 
Roth-Daniek, Sell, England, & Kern, 2012).
The disadvantage of the creams is that they require multiple, 
daily applications which greatly decreases patient compliance. It 
may also induce a painful burning sensation that will discourage 
its application and hasn’t even been proven to be an effective 
analgesic because of its low dosage (Backonja, et al., 2008).
Conclusions
The ingenuity that is being employed to find pathology and tech-
niques suited to capsaicin treatment is astounding and there is 
no doubt that the scientific community will continue to come 
up with new ways to use the unique capabilities of capsaicin 
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to treat other pathologies. However, there is a need for the 
development of a standardized schedule of treatment for using 
capsaicin in a clinical setting (Factor, et al., 2011).
A better understanding of the biology of neuropathic pain 
would also be an advantage for the development of capsa-
icin-based pharmacology. If the mechanisms of pain disorders 
were better understood, treatments could be targeted to di-
rectly counteract them in a technique similar to the molecular 
scalpel being used for cancer-related neuropathic pain.
Perhaps capsaicin could also be adapted for the treatment of 
phantom limb pain (PLP). The source of PLP is a combination of 
sensitization and inflammation that takes place in both the cen-
tral and peripheral nervous systems. Perhaps the desensitizing 
ability of capsaicin could be effective in this scenario by reducing 
peripheral sensitization and central nervous system input.
Capsaicin is a novel pharmacological agent that promises an 
alternative to traditional analgesics and opioids in the treatment 
of neuropathic pain and other pain syndromes. Research into 
capsaicin is fairly recent but clinical data has yielded favorable 
results and new research seems hopeful of making new break-
throughs in techniques and applications of capsaicin in medicine.
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